How do you decide between neoadjuvant or perioperative chemoimmunotherapy, as per Checkmate 816 or KEYNOTE-671, for early-stage NSCLC?
Answer from: Medical Oncologist at Academic Institution
All of us caring for patients with a lung cancer diagnosis face a very challenging “now what” scenario following publications of many studies demonstrating benefits of a neoadjuvant and/or perioperative approach for the treatment of patients with resectable NSCLC with already 2 FDA appro...
Comments
Medical Oncologist at Onc San Antonio Amazing review!
Medical Oncologist at Virginia Oncology Associates Great review of this difficult question. One quest...
Medical Oncologist at Albert Einstein College of Medicine at Montefiore Medical Center Great question - I might just say we have to use c...
Answer from: Medical Oncologist at Academic Institution
Current NCCN guidelines have listed two options in this setting: Nivolumab and platinum doublet chemotherapy every 3 weeks for 3 cycles followed by surgery or Pembrolizumab and platinum doublet chemotherapy every 3 weeks for 4 cycles followed by continued single agent pembrolizumab as adjuvant treat...
Amazing review!
Great review of this difficult question. One quest...
Great question - I might just say we have to use c...